Research analysts at Mitsubishi UFJ Financial Group assumed coverage on shares of PRA Health Sciences (NASDAQ:PRAH) in a research report issued to clients and investors on Friday. The firm set an “overweight” rating and a $102.00 price target on the medical research company’s stock. Mitsubishi UFJ Financial Group’s price target would indicate a potential upside of 14.44% from the company’s current price.
A number of other research firms also recently issued reports on PRAH. Zacks Investment Research downgraded PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Friday, September 15th. SunTrust Banks reaffirmed a “buy” rating and issued a $101.00 price objective on shares of PRA Health Sciences in a research note on Friday, October 27th. KeyCorp reaffirmed a “buy” rating and issued a $93.00 price objective (up previously from $86.00) on shares of PRA Health Sciences in a research note on Monday, October 30th. Mizuho set a $87.00 price objective on PRA Health Sciences and gave the stock a “buy” rating in a research note on Friday, December 1st. Finally, Robert W. Baird reaffirmed a “buy” rating and issued a $88.00 price objective on shares of PRA Health Sciences in a research note on Monday, October 9th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $90.46.
PRA Health Sciences (NASDAQ PRAH) opened at $89.13 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 1.38. PRA Health Sciences has a twelve month low of $53.47 and a twelve month high of $89.81. The company has a market capitalization of $5,527.74, a P/E ratio of 32.07, a P/E/G ratio of 1.51 and a beta of 0.40.
In other news, Director Matthew P. Young sold 5,115 shares of the business’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $79.90, for a total transaction of $408,688.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 2.10% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PRAH. Capital Research Global Investors increased its position in shares of PRA Health Sciences by 318.3% during the 2nd quarter. Capital Research Global Investors now owns 2,175,340 shares of the medical research company’s stock valued at $163,172,000 after purchasing an additional 1,655,336 shares during the last quarter. BlackRock Inc. increased its position in shares of PRA Health Sciences by 28.2% during the 2nd quarter. BlackRock Inc. now owns 3,662,954 shares of the medical research company’s stock valued at $274,759,000 after purchasing an additional 805,573 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of PRA Health Sciences by 55.8% during the 3rd quarter. Wells Fargo & Company MN now owns 1,207,069 shares of the medical research company’s stock valued at $91,943,000 after purchasing an additional 432,449 shares during the last quarter. Hood River Capital Management LLC increased its position in shares of PRA Health Sciences by 80.3% during the 2nd quarter. Hood River Capital Management LLC now owns 619,924 shares of the medical research company’s stock valued at $46,500,000 after purchasing an additional 276,045 shares during the last quarter. Finally, Stephens Investment Management Group LLC increased its position in shares of PRA Health Sciences by 236.9% during the 3rd quarter. Stephens Investment Management Group LLC now owns 391,672 shares of the medical research company’s stock valued at $29,834,000 after purchasing an additional 275,414 shares during the last quarter. 98.49% of the stock is currently owned by hedge funds and other institutional investors.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
